239 related articles for article (PubMed ID: 23434768)
1. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial.
Leonardi S; Truffa AA; Neely ML; Tricoci P; White HD; Gibson CM; Wilson M; Stone GW; Harrington RA; Bhatt DL; Mahaffey KW
Heart; 2013 Sep; 99(17):1282-7. PubMed ID: 23434768
[TBL] [Abstract][Full Text] [Related]
2. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
White HD; Chew DP; Dauerman HL; Mahaffey KW; Gibson CM; Stone GW; Gruberg L; Harrington RA; Bhatt DL
Am Heart J; 2012 Feb; 163(2):182-90.e4. PubMed ID: 22305835
[TBL] [Abstract][Full Text] [Related]
3. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Steg PG; Bhatt DL; Hamm CW; Stone GW; Gibson CM; Mahaffey KW; Leonardi S; Liu T; Skerjanec S; Day JR; Iwaoka RS; Stuckey TD; Gogia HS; Gruberg L; French WJ; White HD; Harrington RA;
Lancet; 2013 Dec; 382(9909):1981-92. PubMed ID: 24011551
[TBL] [Abstract][Full Text] [Related]
4. Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting.
Vranckx P; Farooq V; Garg S; Van Es GA; Silber S; Windecker S; Stone GW; Serruys PW
Heart; 2012 Oct; 98(19):1424-30. PubMed ID: 22821273
[TBL] [Abstract][Full Text] [Related]
5. Remote ischaemic postconditioning: does it protect against ischaemic damage in percutaneous coronary revascularisation? Randomised placebo-controlled clinical trial.
Carrasco-Chinchilla F; Muñoz-García AJ; Domínguez-Franco A; Millán-Vázquez G; Guerrero-Molina A; Ortiz-García C; Enguix-Armada A; Alonso-Briales JH; Hernández-García JM; de Teresa-Galván E; Jiménez-Navarro MF
Heart; 2013 Oct; 99(19):1431-7. PubMed ID: 23850844
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL
Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.
Tricoci P; Newby LK; Clare RM; Leonardi S; Gibson CM; Giugliano RP; Armstrong PW; Van de Werf F; Montalescot G; Moliterno DJ; Held C; Aylward PE; Wallentin L; Harrington RA; Braunwald E; Mahaffey KW; White HD
JACC Cardiovasc Interv; 2018 May; 11(9):856-864. PubMed ID: 29747915
[TBL] [Abstract][Full Text] [Related]
9. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.
Leonardi S; Lopes RD; Steg PG; Abnousi F; Menozzi A; Prats J; Mangum S; Wilson M; Todd M; Stone GW; Gibson CM; Hamm CW; Price MJ; White HD; Harrington RA; Bhatt DL; Mahaffey KW
Eur Heart J Acute Cardiovasc Care; 2018 Mar; 7(2):158-165. PubMed ID: 27485140
[TBL] [Abstract][Full Text] [Related]
10. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
[TBL] [Abstract][Full Text] [Related]
11. The prognosis of periprocedural myocardial infarction after percutaneous coronary interventions.
Zimarino M; Affinito V
Cardiovasc Revasc Med; 2013; 14(1):32-6. PubMed ID: 23164601
[TBL] [Abstract][Full Text] [Related]
12. With the "universal definition," measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention.
Lim CC; van Gaal WJ; Testa L; Cuculi F; Arnold JR; Karamitsos T; Francis JM; Petersen SE; Digby JE; Westaby S; Antoniades C; Kharbanda RK; Burrell LM; Neubauer S; Banning AP
J Am Coll Cardiol; 2011 Feb; 57(6):653-61. PubMed ID: 21292125
[TBL] [Abstract][Full Text] [Related]
13. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Cavender MA; Bhatt DL; Stone GW; White HD; Steg PG; Gibson CM; Hamm CW; Price MJ; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; Harrington RA;
Circulation; 2016 Sep; 134(10):723-33. PubMed ID: 27482008
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
Leonardi S; Thomas L; Neely ML; Tricoci P; Lopes RD; White HD; Armstrong PW; Giugliano RP; Antman EM; Califf RM; Newby LK; Mahaffey KW
J Am Coll Cardiol; 2012 Dec; 60(22):2296-304. PubMed ID: 23122801
[TBL] [Abstract][Full Text] [Related]
15. Cangrelor for treatment during percutaneous coronary intervention.
Oestreich JH; Dobesh PP
Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
[TBL] [Abstract][Full Text] [Related]
16. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
Eisen A; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
Int J Cardiol; 2018 Jan; 250():49-55. PubMed ID: 29030140
[TBL] [Abstract][Full Text] [Related]
17. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
[TBL] [Abstract][Full Text] [Related]
18. Periprocedural type IVa myocardial infarction and the importance of platelet inhibition.
Shah AS; Mills NL; Newby DE
Heart; 2013 Sep; 99(17):1225-6. PubMed ID: 23591669
[No Abstract] [Full Text] [Related]
19. Early versus delayed percutaneous coronary intervention for patients with non-ST segment elevation acute coronary syndrome: a meta-analysis of randomized controlled clinical trials.
Rajpurohit N; Garg N; Garg R; Choudhary A; Fresen J; Boren S; Dellsperger KC; Webel R; Aggarwal K; Alpert MA
Catheter Cardiovasc Interv; 2013 Feb; 81(2):223-31. PubMed ID: 22488783
[TBL] [Abstract][Full Text] [Related]
20. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).
Moussa ID; Klein LW; Shah B; Mehran R; Mack MJ; Brilakis ES; Reilly JP; Zoghbi G; Holper E; Stone GW;
Catheter Cardiovasc Interv; 2014 Jan; 83(1):27-36. PubMed ID: 23894025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
